The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret

European Journal of Pharmacology

Volumn 321, Issue 2, 1997, Pages 209-216

  Singh, Lakhbir ^a   Field, Mark J ^a   Hughes, John ^a   Kuo, Be Sheng ^b   Suman Chauhan, Nirmala ^a   Tuladhar, Bishwa R ^c   Wright, D Scott ^b   Naylor, Robert J ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Brain penetration; Nausea; Ondansetron; Oral bioavailability; Radioligand binding; Retching; t( 1 4 ); Vomiting

Indexed keywords

[2 (1H INDOL 3 YLMETHYL) 1 (1 PHENYLETHYLCARBAMOYL)ETHYL]CARBAMIC ACID BENZOFURAN 2 YLMETHYL ESTER; CISPLATIN; NEUROKININ 1 RECEPTOR; ONDANSETRON; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SUBSTANCE P; SUBSTANCE P, SAR(9) MET(O2)(11); SUBSTANCE P, SAR(9)-MET(O2)(11)-; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; FEMALE; FERRET; GERBIL; GUINEA PIG; HAMSTER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LAMB; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; CHO CELL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE; SENSITIVITY AND SPECIFICITY; SHEEP; SWINE; TIME; WISTAR RAT;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; CHO CELLS; CISPLATIN; CRICETINAE; DOGS; FEMALE; FERRETS; GERBILLINAE; GUINEA PIGS; HUMANS; MALE; MICE; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; SENSITIVITY AND SPECIFICITY; SHEEP; SUBSTANCE P; SWINE; TIME FACTORS; TRYPTOPHAN; VOMITING;

EID: 0030615061     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00950-8     Document Type: Article

References (28)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis, Drugs 42, 551.
2. 3 Receptor Antagonists, eds. F.D. King, B. Jones and G.J. Sanger (CRS Press, New York, NY) p. 255.
3. Andrews, P.L.R., W.G. Rapeport and G.J. Sanger, 1988, Neuropharmacology of emesis induced by anti-cancer therapy, Trends Pharmacol. Sci. 9, 334.
4. 3 receptor antagonist BRL 43694, Br. J. Cancer 58, 644.
5. 1 receptor antagonist, CP-99,994, in ferrets, Eur. J. Pharmacol. 249, R3.
6. Boyle, S., S. Guard, M. Higginbottom, D.C. Horwell, W. Howson, A.T. McKnight, K. Martin, M.C. Pritchard, J. O'Toole, J. Raphy, D.C. Rees, E. Roberts, K.J. Watling, G.N. Woodruff and J. Hughes, 1994, Rational design of high affinity tachykinin NK l receptor antagonists, Bio. Med. Chem. 2, 357.
7. 1 receptor activation in gerbils, Eur. J. Pharmacol. 253, 245.
8. Fiore, J.J. and R.J. Gralla, 1984, Pharmacologic treatment of chemotherapy-induced nausea and vomiting, Cancer Invest. 2, 351.
9. Gandara, D.R., W.H. Harvey, G.G. Monghan, E.A. Perez and P.J. Hesketh, 1993, Delayed emesis following high-dose cisplatin a double-blind randomised comparative trial of ondansetron (GR-38032F) versus placebo, Eur. J. Cancer 29A, S35.
10. 1 receptor antagonists is mediated centrally in the ferret, Br. J. Pharmacol. 112, 516P.
11. 1 receptor antagonist GR203040, Br. J. Pharmacol. 116, 3158.
12. Graham, E.A., M.P. Turpin and C.M. Stubbs, 1993, Characterisation of the tachykinin-induced hindlimb thumping response in gerbils, Neuropepeptides 24, P100.
13. Guard, S., S.J. Boyle, K.W. Tang, K.J. Watling, A.T. McKnight and G.N. Woodruff, 1993a, The interaction of the NK1 receptor antagonist CP96,345 with L-type calcium channels and its functional consequences, Br. J. Pharmacol. 110, 385.
14. 2 binding sites in hamster and rabbit urinary bladder, Eur. J. Pharmacol. 232, 287.
15. 1 antagonists are centrally mediated, Can. J. Physiol. Pharmacol. 72, P45.
16. Hickok, T.J. and G.R. Morrow, 1993, A biobehavioral model of patient-reported nausea: implications for clinical practise, Adv. Med. Psychother. 6, 227.
17. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret, Br. J. Pharmacol. 97, 247.
18. Kris, M.G., L.B. Tyson, R.A. Clark and R.J. Gralla, 1992, Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase-II study and a review of completed trails to manage delayed emesis, Cancer 70, 1012.
19. Morrow, G.R., 1989, Chemotherapy-related nausea and vomiting: etiology and management, Cancer J. Clin. 39, 89.
20. Morrow, G.R., J.T. Hickok and S.N. Rosenthal, 1995, Progress in reducing nausea and emesis, Cancer 76, 343.
21. Rudd, J.A., C.C. Jordan and R.J. Naylor, 1994, Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis, Eur. J. Pharmacol. 262, R1.
22. Rudd, J.A. and R.J. Naylor, 1996, An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret, Br. J. Pharmacol. 118, 209.
23. 1 receptor antagonists, Eur. J. Pharmacol. 265, 179.
24. 2+ channels, Eur. J. Pharmacol. 215, 351.
25. 7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 269, 65.
26. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret, Eur. J. Pharmacol. 250, R5.
27. 1 receptor, Br. J. Pharmacol. 115, 84.
28. Watson, J.W., A. Nagahisa, J.B. Lucot and P.L.R. Andrews, 1996, The tachykinins and emesis: towards complete control?, in: Serotonin and the Scientific Basis of Antiemetic Therapy, eds. D.J.M. Reynolds, P.L.R. Andrews and C.J. Davis (Oxford Clinical Communications, Oxford) p. 233.